Item 1A. Risk Factors
ITEM 1A. RISK FACTORS
In addition to the other information set forth in
this Quarterly Report on Form 10-Q, consider the risk factors discussed in Part 1, “Item 1A. Risk Factors” in the Company’s
2024 Form 10-K and the risk factors discussed in Item 1A of this Quarterly Report on Form 10-Q, which could materially affect our business,
financial condition or future results. The risks described in the aforementioned reports are not the only risks facing the Company. Additional
risks and uncertainties not currently known to the Company or that it currently deems to be not material also may materially adversely
affect the Company’s business, financial condition, and/or operating results.
The following are the risk factors that have materially
changed from our risk factors included in our 2024 Form 10-K:
Risks Related to Ownership of Our Common Stock
Our management and directors will be able to exert influence over
our affairs.
As of March 31, 2025, our executive officers and directors
beneficially owned approximately 4.2% of our common stock. These stockholders, if they act together, may be able to influence our management
and affairs and all matters requiring stockholder approval, including significant corporate transactions. This concentration of ownership
may have the effect of delaying or preventing a change in control and might affect the market price of our common stock.
The market price of our common stock has been volatile over the past
year and may continue to be volatile.
The market price and trading volume of our common stock
has been volatile over the past year and it may continue to be volatile. Over the past year, our common stock has traded as low as $3.01
and as high as $10.69 per share. We cannot predict the price at which our common stock will trade in the future and it may decline. The
price at which our common stock trades may fluctuate significantly and may be influenced by many factors, including our financial results;
developments generally affecting our industry; general economic, industry and market conditions, and our customers; the depth and liquidity
of the market for our common stock; investor perceptions of our business; reports by industry analysts; announcements by other market
participants, including, among others, investors, our competitors, and our customers; regulatory action affecting our business; and the
impact of other “Risk Factors” discussed herein and in our 2024 Form 10-K. In addition, changes in the trading price of our
common stock may be inconsistent with our operating results and outlook. The volatility of the market price of our common stock may be
inconsistent with our operating results and outlook. The volatility of the market price of our common stock may adversely affect investors’
ability to purchase or sell shares of our common stock.
Risks Relating to Our Financial Position
and Capital Requirements
We have incurred significant operating losses in most years since
our inception and anticipate that we will incur continued losses for the foreseeable future.
We have focused a significant portion of our efforts
on developing TLANDO and more recently on LPCN 1154, LPCN 1148, and LPCN 1144. We have funded our operations to date through sales of
our equity securities, debt and payments received under our license and collaboration arrangements. We have incurred losses in most years
since our inception. As of March 31, 2025, we had an accumulated deficit of $201.6 million. Substantially all of our operating losses
resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated
with our operations. These losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’
equity. We expect to continue to incur significant research and development expenses in connection with clinical trials associated with
LPCN 1154, and potentially with LPCN 2401, LPCN 2101, LPCN 2203, LPCN 1148, LPCN 1144 and LPCN 1107, if further clinical trials are initiated.
As a result, we expect to continue to incur significant operating losses for the foreseeable future as we evaluate further clinical development
of LPCN 1154, LPCN 2401, LPCN 2101, LPCN 2203, and possibly LPCN 1148, LPCN 1144, and LPCN 1107, in addition to our other programs and
continued research efforts. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are
unable to predict the extent of any future losses or when we will become profitable, if at all.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.